Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pharmacological targeting of BET bromodomain proteins in acute myeloid leukemia and malignant lymphomas: from molecular characterization to clinical applications

  • Reyes Garau, Diana
  • Ribeiro Lima, Marcelo
  • Roue, Gael
Bromodomain and extra-terminal domain; BRD2; BRD4, Bromodominio y dominio extra terminal; BRD2; BRD4, Bromodomini i domini extra terminal; BRD2; BRD4, Abstract: Alterations in protein-protein and DNA-protein interactions and abnormal chromatin remodeling are a major cause of uncontrolled gene transcription and constitutive activation of critical signaling pathways in cancer cells. Multiple epigenetic regulators are known to be deregulated in several hematologic neoplasms, by somatic mutation, amplification, or deletion, allowing the identification of specific epigenetic signatures, but at the same time providing new therapeutic opportunities. While these vulnerabilities have been traditionally addressed by hypomethylating agents or histone deacetylase inhibitors, pharmacological targeting of bromodomain-containing proteins has recently emerged as a promising approach in a number of lymphoid and myeloid malignancies. Indeed, preclinical and clinical studies highlight the relevance of targeting the bromodomain and extra-terminal (BET) family as an e_cient strategy of target transcription irrespective of the presence of epigenetic mutations. Here we will summarize the main advances achieved in the last decade regarding the preclinical and clinical evaluation of BET bromodomain inhibitors in hematologic cancers, either as monotherapies or in combinations with standard and/or experimental agents. A mention will finally be given to the new concept of the protein degrader, and the perspective it holds for the design of bromodomain-based therapies., G.R. acknowledges supports from Fondo de Investigación Sanitaria PI15/00102 and PI18/01383, European Regional Development Fund (ERDF) “Una manera de hacer Europa”.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Recent advances in the targeting of epigenetic regulators in b-cell non- Hodgkin lymphoma

  • Ribeiro Lima, Marcelo
  • Reyes Garau, Diana
  • Armengol, Marc
  • Fernández Serrano, Miranda
  • Roue, Gael
B-cell lymphoma; DNMT; EZH2, Linfoma de células B; DNMT; EZH2, Limfoma de cèl·lules B; DNMT; EZH2, In the last 10 years, major advances have been made in the diagnosis and development of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma (B-NHL), a heterogeneous group of malignancies arising from the mature B lymphocyte compartment. However, most of these entities remain incurable and current treatments are associated with variable efficacy, several adverse events, and frequent relapses. Thus, new diagnostic paradigms and novel therapeutic options are required to improve the prognosis of patients with B-NHL. With the recent deciphering of the mutational landscapes of B-cell disorders by high-throughput sequencing, it came out that different epigenetic deregulations might drive and/or promote B lymphomagenesis. Consistently, over the last decade, numerous epigenetic drugs (or epidrugs) have emerged in the clinical management of B-NHL patients. In this review, we will present an overview of the most relevant epidrugs tested and/or used so far for the treatment of different subtypes of B-NHL, from first-generation epigenetic therapies like histone acetyl transferases (HDACs) or DNA-methyl transferases (DNMTs) inhibitors to new agents showing selectivity for proteins that are mutated, translocated, and/or overexpressed in these diseases, including EZH2, BET, and PRMT. We will dissect the mechanisms of action of these epigenetic inhibitors, as well as the molecular processes underlying their lack of efficacy in refractory patients. This review will also provide a summary of the latest strategies being employed in preclinical and clinical settings, and will point out the most promising lines of investigation in the field., The authors received financial support from Fondo de Investigacion Sanitaria PI15/00102 and PI18/01383, European Regional Development Fund (ERDF) "Una manera de hacer Europa" (to GR). The authors received fundings from TG Therapeutics and Celgene Corp to support researches unrelated to the present work. Funders were involved neither in the design, nor in the writing of this review.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacological targeting of bet bromodomain proteins in acute myeloid leukemia and malignant lymphomas, From molecular characterization to clinical applications

  • Reyes-Garau, D.
  • Ribeiro, Marcelo L.|||0000-0003-4529-7832
  • Roué, Gaël|||0000-0003-0245-2257
A25in25proarENG-pr910210011and DNA-protein interactions and abnormal chromatin remodeling are a major cause of uncontrolled gene transcription and constitutive activation of critical signaling pathways in cancer cells. Multiple epigenetic regulators are known to be deregulated in several hematologic neoplasms, by somatic mutation, amplification, or deletion, allowing the identification of specific epigenetic signatures, but at the same time providing new therapeutic opportunities. While these vulnerabilities have been traditionally addressed by hypomethylating agents or histone deacetylase inhibitors, pharmacological targeting of bromodomain-containing proteins has recently emerged as a promising approach in a number of lymphoid and myeloid malignancies. Indeed, preclinical and clinical studies highlight the relevance of targeting the bromodomain and extra-terminal (BET) family as an efficient strategy of target transcription irrespective of the presence of epigenetic mutations. Here we will summarize the main advances achieved in the last decade regarding the preclinical and clinical evaluation of BET bromodomain inhibitors in hematologic cancers, either as monotherapies or in combinations with standard and/or experimental agents. A mention will finally be given to the new concept of the protein degrader, and the perspective it holds for the design of bromodomain-based therapies.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma

  • Ribeiro, Marcelo L.|||0000-0003-4529-7832
  • Reyes Garau, Diana|||0000-0002-6124-8953
  • Armengol, Marc Antoni|||0000-0001-5206-9139
  • Roué, Gaël|||0000-0003-0245-2257
In the last 10 years, major advances have been made in the diagnosis and development of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma (B-NHL), a heterogeneous group of malignancies arising from the mature B lymphocyte compartment. However, most of these entities remain incurable and current treatments are associated with variable efficacy, several adverse events, and frequent relapses. Thus, new diagnostic paradigms and novel therapeutic options are required to improve the prognosis of patients with B-NHL. With the recent deciphering of the mutational landscapes of B-cell disorders by high-throughput sequencing, it came out that different epigenetic deregulations might drive and/or promote B lymphomagenesis. Consistently, over the last decade, numerous epigenetic drugs (or epidrugs) have emerged in the clinical management of B-NHL patients. In this review, we will present an overview of the most relevant epidrugs tested and/or used so far for the treatment of different subtypes of B-NHL, from first-generation epigenetic therapies like histone acetyl transferases (HDACs) or DNA-methyl transferases (DNMTs) inhibitors to new agents showing selectivity for proteins that are mutated, translocated, and/or overexpressed in these diseases, including EZH2, BET, and PRMT. We will dissect the mechanisms of action of these epigenetic inhibitors, as well as the molecular processes underlying their lack of efficacy in refractory patients. This review will also provide a summary of the latest strategies being employed in preclinical and clinical settings, and will point out the most promising lines of investigation in the field.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma

  • Quinet, Grégoire
  • Xolalpa, Wendy
  • Reyes Garau, Diana|||0000-0002-6124-8953
  • Profitós-Pelejà, Núria|||0000-0001-8923-6025
  • Azkargorta, Mikel
  • Ceccato, Laurie
  • Gonzalez-Santamarta, María
  • Marsal, Maria|||0000-0001-9678-8717
  • Andilla, Jordi
  • Aillet, Fabienne
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Elortza, Felix|||0000-0001-8839-5438
  • Loza-Alvarez, Pablo|||0000-0002-3129-1213
  • Sola, Brigitte|||0000-0001-7278-9651
  • Coux, Olivier|||0000-0001-8455-3849
  • Matthiesen, Rune|||0000-0002-6353-2616
  • Roué, Gaël|||0000-0003-0245-2257
  • Rodriguez, Manuel S.
Protein ubiquitylation coordinates crucial cellular events in physiological and pathological conditions. A comparative analysis of the ubiquitin proteome from bortezomib (BTZ)-sensitive and BTZ-resistant mantle cell lymphoma (MCL) revealed an enrichment of the autophagy-lysosome system (ALS) in BTZ-resistant cells. Pharmacological inhibition of autophagy at the level of lysosome-fusion revealed a constitutive activation of proteaphagy and accumulation of proteasome subunits within autophagosomes in different MCL cell lines with acquired or natural resistance to BTZ. Inhibition of the autophagy receptor p62/SQSTM1 upon verteporfin (VTP) treatment disrupted proteaphagosome assembly, reduced co-localization of proteasome subunits with autophagy markers and negatively impacted proteasome activity. Finally, the silencing or pharmacological inhibition of p62 restored the apoptosis threshold at physiological levels in BTZ-resistant cells both in vitro and in vivo. In total, these results demonstrate for the first time a proteolytic switch from the ubiquitin-proteasome system (UPS) to ALS in B-cell lymphoma refractory to proteasome inhibition, pointing out a crucial role for proteaphagy in this phenomenon and paving the way for the design of alternative therapeutic venues in treatment-resistant tumors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells

  • Body, Simon
  • Esteve-Arenys, Anna
  • Miloudi, Hadjer
  • Recasens-Zorzo, C.lara
  • Tchakarska, Guergana
  • Moros, Alexandra
  • Bustany, Sophie
  • Vidal-Crespo, Anna
  • Rodriguez, Vanina
  • Lavigne, Régis
  • Com, Emmanuelle
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Weigert, Oliver
  • Sanjuan-Pla, Alejandra
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Marcq, Bénédicte
  • Picquenot, Jean-Michel
  • Pérez-Galán, Patricia|||0000-0003-3895-5024
  • Jardin, Fabrice
  • Roué, Gaël|||0000-0003-0245-2257
  • Sola, Brigitte|||0000-0001-7278-9651
Mantle cell lymphoma (MCL) is a hematologic neoplasm characterised by the t(11;14)(q13;q32) translocation leading to aberrant cyclin D1 expression. The cell functions of cyclin D1 depend on its partners and/or subcellular distribution, resulting in different oncogenic properties. We observed the accumulation of cyclin D1 in the cytoplasm of a subset of MCL cell lines and primary cells. In primary cells, this cytoplasmic distribution was correlated with a more frequent blastoid phenotype. We performed immunoprecipitation assays and mass spectrometry on enriched cytosolic fractions from two cell lines. The cyclin D1 interactome was found to include several factors involved in adhesion, migration and invasion. We found that the accumulation of cyclin D1 in the cytoplasm was associated with higher levels of migration and invasiveness. We also showed that MCL cells with high cytoplasmic levels of cyclin D1 engrafted more rapidly into the bone marrow, spleen, and brain in immunodeficient mice. Both migration and invasion processes, both in vivo and in vitro, were counteracted by the exportin 1 inhibitor KPT-330, which retains cyclin D1 in the nucleus. Our data reveal a role of cytoplasmic cyclin D1 in the control of MCL cell migration and invasion, and as a true operator of MCL pathogenesis.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Recent advances in the targeting of epigenetic regulators in b-cell non- Hodgkin lymphoma

  • Ribeiro Lima, Marcelo
  • Reyes Garau, Diana
  • Armengol, Marc
  • Fernández Serrano, Miranda
  • Roue, Gael
B-cell lymphoma; DNMT; EZH2, Linfoma de células B; DNMT; EZH2, Limfoma de cèl·lules B; DNMT; EZH2, In the last 10 years, major advances have been made in the diagnosis and development of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma (B-NHL), a heterogeneous group of malignancies arising from the mature B lymphocyte compartment. However, most of these entities remain incurable and current treatments are associated with variable efficacy, several adverse events, and frequent relapses. Thus, new diagnostic paradigms and novel therapeutic options are required to improve the prognosis of patients with B-NHL. With the recent deciphering of the mutational landscapes of B-cell disorders by high-throughput sequencing, it came out that different epigenetic deregulations might drive and/or promote B lymphomagenesis. Consistently, over the last decade, numerous epigenetic drugs (or epidrugs) have emerged in the clinical management of B-NHL patients. In this review, we will present an overview of the most relevant epidrugs tested and/or used so far for the treatment of different subtypes of B-NHL, from first-generation epigenetic therapies like histone acetyl transferases (HDACs) or DNA-methyl transferases (DNMTs) inhibitors to new agents showing selectivity for proteins that are mutated, translocated, and/or overexpressed in these diseases, including EZH2, BET, and PRMT. We will dissect the mechanisms of action of these epigenetic inhibitors, as well as the molecular processes underlying their lack of efficacy in refractory patients. This review will also provide a summary of the latest strategies being employed in preclinical and clinical settings, and will point out the most promising lines of investigation in the field., The authors received financial support from Fondo de Investigacion Sanitaria PI15/00102 and PI18/01383, European Regional Development Fund (ERDF) "Una manera de hacer Europa" (to GR). The authors received fundings from TG Therapeutics and Celgene Corp to support researches unrelated to the present work. Funders were involved neither in the design, nor in the writing of this review.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Pharmacological targeting of BET bromodomain proteins in acute myeloid leukemia and malignant lymphomas: from molecular characterization to clinical applications

  • Reyes Garau, Diana
  • Ribeiro Lima, Marcelo
  • Roue, Gael
Bromodomain and extra-terminal domain; BRD2; BRD4, Bromodominio y dominio extra terminal; BRD2; BRD4, Bromodomini i domini extra terminal; BRD2; BRD4, Abstract: Alterations in protein-protein and DNA-protein interactions and abnormal chromatin remodeling are a major cause of uncontrolled gene transcription and constitutive activation of critical signaling pathways in cancer cells. Multiple epigenetic regulators are known to be deregulated in several hematologic neoplasms, by somatic mutation, amplification, or deletion, allowing the identification of specific epigenetic signatures, but at the same time providing new therapeutic opportunities. While these vulnerabilities have been traditionally addressed by hypomethylating agents or histone deacetylase inhibitors, pharmacological targeting of bromodomain-containing proteins has recently emerged as a promising approach in a number of lymphoid and myeloid malignancies. Indeed, preclinical and clinical studies highlight the relevance of targeting the bromodomain and extra-terminal (BET) family as an e_cient strategy of target transcription irrespective of the presence of epigenetic mutations. Here we will summarize the main advances achieved in the last decade regarding the preclinical and clinical evaluation of BET bromodomain inhibitors in hematologic cancers, either as monotherapies or in combinations with standard and/or experimental agents. A mention will finally be given to the new concept of the protein degrader, and the perspective it holds for the design of bromodomain-based therapies., G.R. acknowledges supports from Fondo de Investigación Sanitaria PI15/00102 and PI18/01383, European Regional Development Fund (ERDF) “Una manera de hacer Europa”.